Lupin allots 2642 equity shares under ESOP on 19 November 2024. In view of the above, the issued and paid-up share capital of the Company has been increased to Rs 91,23,95,126 consisting of 45,61,97,563 equity shares of Rs 2/- each.Powered by Capital Market - Live News

Net profit of Lupin rose 74.12% to Rs 852.63 crore in the quarter ended September 2024 as against Rs 489.67 crore during the previous quarter ended September 2023. Sales rose 11.29% to Rs 5497.01 crore in the quarter ended September 2024 as against Rs 4939.23 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales5497.014939.23 11 OPM %24.3818.58 - PBDT1311.78877.52 49 PBT1054.86629.67 68 NP852.63489.67 74 Powered by Capital Market - Live News

Lupin has allotted 51,609 equity shares under ESOP on 23 October 2024. The issued and paid-up capital of the Company has been increased to Rs 91,23,89,842 consisting of 45,61,94,921 equity shares of Rs 2/- each.Powered by Capital Market - Live News

Lupin will hold a meeting of the Board of Directors of the Company on 7 November 2024.Powered by Capital Market - Live News

Lupin announced the launch of the first generic version of Pred Forte� (Prednisolone Acetate) Ophthalmic Suspension USP, 1% in the United States. Being the first generic to be approved and launched, the company is entitled to 180-day competitive generic therapy (CGT) exclusivity. Prednisolone Acetate Ophthalmic Suspension USP, 1% is a generic equivalent of Pred Forte� Ophthalmic Suspension, 1% of AbbVie, Inc. and is indicated for the treatment of steroid responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. Pred Forte� had estimated annual sales of USD 198 million in the U.S. (IQVIA MAT August 2024). Powered by Capital Market - Live News